Clinical Trial Update: A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update on reduced-toxicity, allogeneic unrelated donor stem cell transplantation for severe sickle cell disease; study terminated with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Sickle Cell Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-04-03